Senseonics has signed a Memorandum of Understanding to take over the commercialization of its Eversense 365 continuous glucose monitoring system from Ascensia Diabetes Care, effective January 1, 2026.

Target Information

Senseonics Holdings, Inc. (NYSE American: SENS) is a pioneering medical technology company specializing in long-term implantable continuous glucose monitoring (CGM) systems designed for patients with diabetes. Recently, Senseonics announced a Memorandum of Understanding (MOU) to take over the commercialization and distribution of its flagship product, Eversense 365, from Ascensia Diabetes Care, a member of the PHC Group. This transition is set to take effect on January 1, 2026, allowing Senseonics to assume responsibility for global sales, marketing, and commercialization of Eversense solutions.

Since 2020, Ascensia Diabetes Care has held exclusive worldwide distribution rights for Eversense products. The proposed transition will also include transitional support as Senseonics establishes its operations in markets outside the U.S. Brian Hansen, currently the President of CGM at Ascensia, will join Senseonics as their Chief Commercial Officer, ensuring continuity in leadership and expertise for the Eversense brand.

Industry Overview in the United States

The U.S. diabetes management market is rapidly evolving, driven by increasing awareness and advancements in technology. Continuous glucose monitoring has gained traction among clinicians and patients, with an emphasis on